Ori Biotech officials say the company has launched its Preferred Partner Network (PPN), bringing together academic medical centers (AMCs) and contract development and manufacturing organizations ...

MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 ...

Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, and ImmuXell Biotech, a Shanghai-based clinical-stage cell therapy company, today announced their strategic partnership ...

After completing his PhD on increasing monoclonal antibody titers, Farlan Veraitch realized that manufacturing biologics was not the right path for him. The next great frontier, Veraitch envisioned, ...

MaxCyte, Inc. and Oribiotech Ltd. have announced a strategic collaboration to improve efficiency and scalability in cell therapy manufacturing. This partnership will integrate MaxCyte's ExPERT™ ...

LONDON and BAD HOMBURG, Germany, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, and Fresenius Kabi, an operating company of ...

This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. In this episode, Fierce Pharma’s Fraiser Kansteiner sits down with ...

LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Oribiotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, announces the first customer deliveries of the new IRO ® platform, ...

ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, ...

Ori Biotech, a leader in cell and gene therapy (CGT) manufacturing technology, and ImmuXell Biotech, a Shanghai-based clinical-stage cell therapy company, today announced their strategic partnership ...